Physician profile
Anthony Nappi
NPI 1457541583
$12,399.28
in general payments reported to CMS, 2019-2025
35 companies · $4,372 in 2025
The $4,372 reported for 2025 was more than what 81% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,593 · 2020: $846 · 2021: $808 · 2022: $1,081 · 2023: $2,147 · 2024: $1,552 · 2025: $4,372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,723 · Travel and Lodging: $348.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,723.11 |
| Travel and Lodging | $348.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $5,299.30 | 2019-2025 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| Aop Health US, LLC | $1,967.34 | 2025 | Rapiblyk |
| Boston Scientific Corporation | $1,554.19 | 2019-2025 | Versacross Access Solution, Watchman Flx, General - Therapies |
| Abbott Laboratories | $499.87 | 2019-2025 | Navitor, Mitraclip, Perclose Prostyle |
| Novartis Pharmaceuticals Corporation | $418.92 | 2019-2025 | |
| Abiomed | $338.47 | 2020-2025 | Impella |
| Janssen Pharmaceuticals, INC | $255.09 | 2019-2024 | Xarelto |
| Chiesi USA, INC. | $234.22 | 2019-2024 | Kengreal, Cleviprex |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $205.60 | 2019-2023 | Lifevest |
| Astellas Pharma US INC | $192.60 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $166.24 | 2019-2025 | Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.42 | 2019-2025 | Jardiance |
| Amgen INC. | $147.04 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $145.02 | 2019-2025 | Camzyos, Eliquis |
| Scpharmaceuticals INC. | $91.99 | 2025 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $86.12 | 2019 | |
| Pfizer INC. | $70.84 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $70.59 | 2019-2025 | Evkeeza |
| Bridgebio Pharma, INC. | $52.12 | 2025 | Attruby |
| Medtronic, INC. | $47.14 | 2021-2024 | Symplicity G3 |
| Alnylam Pharmaceuticals INC. | $45.18 | 2024 | Onpattro |
| Medtronic Vascular, INC. | $42.67 | 2019-2020 | |
| Otsuka America Pharmaceutical, INC. | $42.35 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $37.88 | 2025 | |
| Cvrx, INC. | $35.24 | 2025 | Barostim Neo System |
| Cardiva Medical, INC. | $26.33 | 2023 | Cardiva Vascade Mvp Vvcs 6-12f |
| Baxter Healthcare | $25.99 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Cardiovascular Systems INC. | $23.60 | 2019 | |
| Esperion Therapeutics, INC. | $21.69 | 2025 | Nexletol |
| Rayner Intraocular Lenses Limited | $21.42 | 2023 | Rayone Spheric, Omidria, Rayone Aspheric |
| Sanofi-Aventis U.S. LLC | $20.81 | 2019 | |
| Terumo Medical Corporation | $17.92 | 2019 | |
| Merck Sharp & Dohme LLC | $16.94 | 2025 | Verquvo |
| Merit Medical Systems INC | $16.92 | 2025 | Foundation, Kits & Packs |
| Lexicon Pharmaceuticals, INC. | $14.22 | 2023 | Inpefa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Nappi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.